Logo
D

DEVYSER AB

Devyser is specialized in the development, manufacture, and sales of diagnostic kits. The products are sold to routine diagnostic laboratories in more than 45 countries. The products are used for advanced DNA testing in the hereditary disease, oncology and post-transplantation monitoring fields, to enable targeted cancer treatment, the diagnosis of a large number of genetic diseases, and transplant patient follow-up. Devyser's product development focuses on simplifying and streamlining advanced testing processes to improve throughput, reduce hands-on time and produce accurate and trusted results. Devyser was founded in 2004 and is based in Stockholm, Sweden. Devyser's shares are listed on Nasdaq First North Growth Market Stockholm (ticker: DVYSR). The company's Certified Adviser is Redeye AB, e-mail address [email protected] and telephone number +46 8 121 576 90.
Country/AreaSweden
Company Emailhr@devyser.com
IndustryBiotechnologyBusiness ServicesBusiness Services General
Company website
Company phone+46 856215850
Established2004
Company Revenue$17,293,000
Number of employees25
SIC Code87873
NAICS Code54541
https://www.linkedin.com/company/devyser-abhttps://twitter.com/devyserhttp://www.facebook.com/1180372362040569https://www.instagram.com/devyser

Company News

Invitation to audiocast for Devyser’s Q3 report 2023
On Thursday November 9, at 09:00 CET, Devyser Diagnostics AB will host an online presentation of its Q3 2023 report (which will have been published earlier on November 9, at 07.30 CET). The presentation will be held in English. Dial-in number to the teleconference and a conference ID will be received by registering on the link below: https://conference.financialhearings.com/teleconference/?id=5003819 The presentation will also be webcast and can be accessed from the following web address:
dateOct 30, 2023
Devyser and Thermo Fisher Scientific collaborate to promote laboratory services to advance pharmaceutical research
Devyser and Thermo Fisher Scientific have entered into a collaboration agreement to promote laboratory services. The goal is to partner with pharmaceutical companies to support their development projects utilising Devyser’s unique assays in its CLIA-certified laboratory. The companies will work together to promote the Devyser laboratory services to support and advance research and development for pharmaceutical companies. “We are very excited to enter into this agreement. Being able to support p
dateSep 13, 2023
Devyser and Thermo Fisher Scientific expand the collaboration for post-transplant NGS products by adding Brazil
Devyser and Thermo Fisher Scientific have agreed to expand commercial collaboration by including Brazil in the exclusive collaboration and distribution agreement for Devyser’s post-transplant portfolio of NGS products. In addition to North America and Europe, Thermo Fisher will now exclusively market and sell Devyser’s transplantation products under combined brands also in Brazil. “We are very excited to enter into this agreement. Up to now, our products have not been available in the large
dateSep 6, 2023
Devyser Diagnostics AB publishes quarterly report for the period April to June 2023
“The second quarter of the year saw an improvement in EBIT compared with recent quarters, continued high gross margins, strong growth and an exclusive collaboration and distribution agreement with US-based Thermo Fisher Scientific. Two new oncology products and one new transplant product were launched during the quarter. Our CLIA-certified laboratory in Atlanta was inaugurated and the first patient test was carried out in this laboratory.” Fredrik Alpsten, CEO, Devyser The quarter from April to
dateAug 23, 2023
Invitation to audiocast for Devyser’s Q2 report 2023
On Wednesday August 23, at 09:00 CET, Devyser Diagnostics AB will host an online presentation of its Q2 2023 report (which will have been published earlier on August 23, at 07.30 CET). The presentation will be held in English. Dial-in number to the teleconference and a conference ID will be received by registering on the link below: https://conference.financialhearings.com/teleconference/?id=200933 The presentation will also be webcast and can be accessed from the following web address:
dateAug 14, 2023

Web Summary

Q1: What is the address of Devyser AB?
A1: The company is based in Stockholm, Sweden with eight in-house sales offices in Europe and the US.

Q2: What products does Devyser develop, manufacture, and sell?
A2: Devyser develops, manufactures, and sells diagnostic solutions and analysis services to clinical laboratories in more than 65 countries. Their products are used for advanced genetic testing in various fields such as hereditary disease, oncology, and transplant.

Q3: What is the industry of Devyser AB?
A3: Devyser operates in the biotechnology and diagnostics industry, specifically in the field of genetic testing and analysis services.

Q4: What services does Devyser offer to its customers?
A4: In addition to developing and selling diagnostic solutions, Devyser also provides analysis services to clinical laboratories. They aim to simplify genetic testing processes, improve sample throughput, minimize hands-on time, and deliver rapid results.

Q5: What is the goal of Devyser's business?
A5: The company's primary goal is for every patient to receive a correct diagnosis in the shortest possible time. Sustainability is also a central part of their business, which is essential for long-term value creation.

Q6: When was Devyser AB founded?
A6: Devyser was founded in 2004.

Q7: What regulatory approval has Devyser received for its RHD product?
A7: In 2024, Devyser received IVDR (In Vitro Diagnostic Regulation) approval for its non-invasive fetal RHD screening product, marking the first approval of a Class D product under the new European regulation.

Q8: How does Devyser's quality management system relate to the IVDR?
A8: In 2022, Devyser's quality management system was certified according to the IVDR, and since then, several of the company's products have been certified according to the IVDR.
Customs Data
As a purchaser
As a Supplier
Disable_icon
Get the Whole details
DisableData_png
Contact
Total found ??? Contacts
All
Boss
Management
Procurement
Other
Disable_icon
Get the Whole details
DisableContact_png